Radiopharm's brain-scan tracer matches MRI in most patients; key accuracy figure still pending
Radiopharm Theranostics says its 18F-RAD101 imaging agent tracked contrast MRI closely in an early cohort and has FDA agreement on one late-stage trial, but the specificity figure is outstanding.
Radiopharm Theranostics has given investors a first look at how its PET imaging agent 18F-RAD101 performs against the current standard for brain metastases, and the commercially relevant news is the regulatory route. The company says it has recently agreed with the US Food and Drug Administration that one Phase 3 imaging study will be needed. No cost, timeline or financing detail for that trial was included in the material reviewed.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Radiopharm Theranostics Ltd ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.